C.R. Bard, Inc. (NYSE:BCR) announced a quarterly dividend on Wednesday, October 11th, RTT News reports. Stockholders of record on Friday, December 8th will be paid a dividend of 0.26 per share by the medical instruments supplier on Friday, December 29th. This represents a $1.04 annualized dividend and a dividend yield of 0.32%.

C.R. Bard has increased its dividend by an average of 6.8% per year over the last three years and has raised its dividend annually for the last 45 consecutive years. C.R. Bard has a dividend payout ratio of 8.8% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect C.R. Bard to earn $12.89 per share next year, which means the company should continue to be able to cover its $1.04 annual dividend with an expected future payout ratio of 8.1%.

Shares of C.R. Bard (NYSE BCR) traded up 0.50% during midday trading on Wednesday, hitting $321.58. The stock had a trading volume of 278,091 shares. The stock has a market cap of $23.37 billion, a price-to-earnings ratio of 42.22 and a beta of 0.58. C.R. Bard has a 1-year low of $203.63 and a 1-year high of $324.58. The firm’s 50-day moving average price is $320.11 and its 200-day moving average price is $306.89.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million for the quarter, compared to the consensus estimate of $976.53 million. During the same quarter in the previous year, the business earned $2.54 EPS. C.R. Bard’s revenue was up 5.2% compared to the same quarter last year. Analysts forecast that C.R. Bard will post $11.81 earnings per share for the current year.

BCR has been the topic of a number of research analyst reports. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a report on Monday, July 31st. Jefferies Group LLC restated a “hold” rating on shares of C.R. Bard in a report on Thursday, August 3rd. BidaskClub downgraded C.R. Bard from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, BMO Capital Markets restated a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $292.00.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/10/11/c-r-bard-inc-declares-quarterly-dividend-of-0-26-bcr.html.

In other C.R. Bard news, insider Timothy P. Collins sold 8,388 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $322.00, for a total transaction of $2,700,936.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $320.00, for a total value of $9,680,640.00. The disclosure for this sale can be found here. Insiders have sold a total of 62,327 shares of company stock worth $19,931,334 in the last quarter. Company insiders own 0.80% of the company’s stock.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Dividend History for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.